XENETIC BIOSCIENCES, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- XENETIC BIOSCIENCES, INC. stock issued during period, value, new issues for the quarter ending 2021-12-31 was $0.00.
- XENETIC BIOSCIENCES, INC. stock issued during period, value, new issues for the quarter ending 2021-09-30 was $11.45M.
- XENETIC BIOSCIENCES, INC. stock issued during period, value, new issues for the quarter ending 2019-12-31 was $13.42M.
- XENETIC BIOSCIENCES, INC. stock issued during period, value, new issues for the quarter ending 2019-09-30 was $0.00.
- XENETIC BIOSCIENCES, INC. stock issued during period, value, new issues for fiscal 2025 was $4.00M.
- XENETIC BIOSCIENCES, INC. stock issued during period, value, new issues for fiscal 2021 was $11.45M, a 111.00% increase from fiscal 2020.
- XENETIC BIOSCIENCES, INC. stock issued during period, value, new issues for fiscal 2020 was $5.43M, a 66.34% decline from fiscal 2019.
- XENETIC BIOSCIENCES, INC. stock issued during period, value, new issues for fiscal 2019 was $16.12M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $4.00M 10-K · filed 2026-03-12 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $11.45M 10-K · filed 2023-03-22 |
| 2021-09-30 | $11.45M 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $5.43M 10-K · filed 2022-03-22 | |
| 2019-12-31 | $13.42M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $16.12M 10-K · filed 2020-03-26 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | |
| 2019-03-31 | $2.70M 10-Q · filed 2019-05-13 | |
| 2015-12-31 | $337.34K 10-K · filed 2017-03-31 | |
| 2014-12-31 | $10.81M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |